Special Issue

Pharmacogenomics and Hypertension: Problems and Prospects

Message from the Guest Editors

Arterial hypertension has a strong underlying hereditary and environmental basis. Treatment has remained empiric, control rates are suboptimal, and there is minimal translation of genetics from the bench to the clinic. Although rare monogenic forms of hypertension with a distinct phenotype were initially well documented and provided specific treatments, the overall genetic risk for hypertension was considered to be polygenetic in origin. The initial GWAS studies could only explain 2% of the overall risk, which led to a degree of nihilism in relation to the pharmacogenetics of hypertension. The aim of this Special Issue is to review and publish cutting-edge research on new developments in the understanding of the genetics of arterial hypertension, the translation of genetic research to the clinic, and future directions for pharmacogenomics. We are soliciting original articles related to understanding the genetic architecture of hypertension, genetic risk scoring, Mendelian randomization, epigenetics, the pharmacokinetics and pharmacodynamics of antihypertensive drugs, translational research, and state-of-the-art manuscripts on the status of pharmacogenomics and future directions.

Guest Editors

Prof. Dr. Brian L. Rayner

Division of Nephrology and Hyertension, University of Cape Town, Cape Town, South Africa

Prof. Dr. Collet Dandara

Platform for Pharmacogenomics Research and Translation (PREMED), South African Medical Research Council & Division of Human Genetics, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

Deadline for manuscript submissions

closed (25 July 2025)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/185469

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

MDPI

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

MDPI

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).